MorphoSys AG announced that its Supervisory Board has appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer (CEO). The appointment will take effect on September 1, 2019. In his new position, Dr. Kress will succeed Dr. Simon Moroney, who had announced his decision not to renew his contract as a member of MorphoSys's Management Board in February 2019 and who will step down as CEO on September 1, 2019. Dr. Moroney will support Dr. Kress during a transition period. Dr. Kress brings comprehensive senior leadership experience of over 10 years in pharmaceutical and biotechnology firms, with a focus on operations and commercialization of innovative products addressing unmet medical needs across diverse disease indications. Dr. Jean-Paul Kress held many senior leadership positions in pharmaceutical and biotechnology firms. Prior to joining MorphoSys, Dr. Kress served as President and Chief Executive Officer at Syntimmune, now a subsidiary of Alexion Pharmaceuticals.